---
document_datetime: 2025-12-29 08:40:33
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/trajenta.html
document_name: trajenta.html
version: success
processing_time: 0.1157511
conversion_datetime: 2025-12-30 08:49:39.592443
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Trajenta

[RSS](/en/individual-human-medicine.xml/65417)

##### Authorised

This medicine is authorised for use in the European Union

linagliptin Medicine Human Authorised

On Monday, 12 January 2026, between 07:00 and 10:00 CET (Amsterdam time), this website will be unavailable due to scheduled maintenance.

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Trajenta](#news-on)
- [More information on Trajenta](#related-medicines)
- [Topics](#topics)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

This is a summary of the European public assessment report (EPAR) for Trajenta. It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Trajenta.

Expand section

Collapse section

## What is Trajenta?

Trajenta is a medicine that contains the active substance linagliptin. It is available as tablets (5 mg).

## What is Trajenta used for?

Trajenta is used to treat type-2 diabetes with the following antidiabetes medicines when blood sugar levels are not already adequately controlled by diet, exercise and these antidiabetes medicines taken alone:

- metformin;
- metformin and a sulphonylurea;
- insulin, either on its own or together with metformin.

Trajenta is also used on its own in patients whose blood sugar levels are not adequately controlled by diet and exercise alone and who cannot be treated with metformin because they cannot tolerate it or because they have kidney problems. The medicine can only be obtained with a prescription.

## How is Trajenta used?

The recommended dose of Trajenta is one tablet once a day. When added to metformin the dose of metformin should remain unchanged, however when combined with a sulphonylurea or insulin, a lower dose of the sulphonylurea or insulin may be considered because of the risk of hypoglycaemia (low blood sugar).

## How does Trajenta work?

Type-2 diabetes is a disease in which the pancreas does not make enough insulin to control the level of glucose (sugar) in the blood or when the body is unable to use insulin effectively. The active substance in Trajenta, linagliptin, is a dipeptidyl-peptidase-4 (DPP-4) inhibitor. It works by blocking the breakdown of 'incretin' hormones in the body. These hormones are released after a meal and stimulate the pancreas to produce insulin. By prolonging the action of incretin hormones in the blood, linagliptin stimulates the pancreas to produce more insulin when blood glucose levels are high. Linagliptin does not work when the blood glucose is low. Linagliptin also reduces the amount of glucose made by the liver, by increasing insulin levels and decreasing the levels of the hormone glucagon. Together, these processes reduce blood glucose levels and help to control type-2 diabetes.

## How has Trajenta been studied?

Five main studies in patients with type-2 diabetes were carried out with Trajenta, comparing the medicine with placebo (a dummy treatment) in combination with metformin (701 patients), in combination with metformin plus a sulphonylurea (1,058 patients), in combination with another antidiabetes medicine pioglitazone (389 patients) and in combination insulin with or without metformin and/or pioglitazone (1235 patients). Trajenta was also compared with placebo when used on its own in 503 patients.

In all studies, the main measure of effectiveness was the change in blood levels of a substance called glycosylated haemoglobin (HbA1c) after 24 weeks of treatment. This gives an indication of how well blood glucose is controlled.

## What benefit has Trajenta shown during the studies?

Trajenta was shown to be more effective than placebo at reducing HbA1c levels in all combinations studied:

- when used in combination with metformin, a reduction of 0.56 percentage points was seen with Trajenta compared with a rise of 0.10 percentage points with placebo;
- when used in combination with a metformin plus a sulphonylurea, a reduction of 0.72 percentage points was seen with Trajenta compared with a reduction of 0.10 percentage points with placebo;
- in combination with pioglitazone, a reduction of 1.25 percentage points was seen with Trajenta compared with a reduction of 0.75 percentage points with placebo;
- in combination with insulin with or without metformin and / or pioglitazone, a reduction of 0.55 percentage points was seen with Trajenta compared with a rise of 0.10 percentage points with placebo.

Trajenta was also more effective than placebo when used on its own, reducing HbA1c levels by 0.46 percentage points compared with a rise of 0.22 percentage points seen with placebo.

## What is the risk associated with Trajenta?

Results from studies show that the overall risk of side effects were similar between Trajenta and placebo (63% versus 60%). The most frequently reported side effect, seen in around 6 out of 100 patients taking Trajenta, was hypoglycaemia. Most cases were mild and none were severe. Hypoglycaemia was seen in around 15 out of 100 patients treated with the triple combination of Trajenta with metformin and a sulphonylurea (around twice as many as the placebo group). For the full list of all side effects reported with Trajenta, see the package leaflet.

Trajenta must not be used in people who are hypersensitive (allergic) to linagliptin or to any of the other ingredients.

## Why has Trajenta been approved?

Based on the results of the main studies, the CHMP concluded that significant benefits in controlling blood glucose levels were seen in the combinations of Trajenta with metformin, with metformin plus a sulphonylurea, and with insulin with or without metformin. Trajenta on its own was also shown to be effective compared with placebo and was considered appropriate for patients who cannot take metformin either due to intolerance or because they have kidney problems. However the benefit of adding Trajenta to pioglitazone treatment was not considered to have been sufficiently established.

The overall risk of side effects with Trajenta was mostly comparable to placebo and the medicine's safety is similar to that of other DPP-4-inhibitor medicines.

The Committee therefore concluded that the benefits of Trajenta outweigh its risks and recommended that it be granted marketing authorisation.

## Other information about Trajenta

The European Commission granted a marketing authorisation valid throughout the European Union for Trajenta on 24 August 2011.

For more information about treatment with Trajenta, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.

Trajenta : EPAR - Summary for the public

English (EN) (76.28 KB - PDF)

**First published:** 06/10/2011

**Last updated:** 15/04/2013

[View](/en/documents/overview/trajenta-epar-summary-public_en.pdf)

[Other languages (21)](#file-language-dropdown-791)

български (BG) (103.51 KB - PDF)

**First published:**

06/10/2011

**Last updated:**

15/04/2013

[View](/bg/documents/overview/trajenta-epar-summary-public_bg.pdf)

español (ES) (75.69 KB - PDF)

**First published:**

06/10/2011

**Last updated:**

15/04/2013

[View](/es/documents/overview/trajenta-epar-summary-public_es.pdf)

čeština (CS) (101.42 KB - PDF)

**First published:**

06/10/2011

**Last updated:**

15/04/2013

[View](/cs/documents/overview/trajenta-epar-summary-public_cs.pdf)

dansk (DA) (74.05 KB - PDF)

**First published:**

06/10/2011

**Last updated:**

15/04/2013

[View](/da/documents/overview/trajenta-epar-summary-public_da.pdf)

Deutsch (DE) (75.74 KB - PDF)

**First published:**

06/10/2011

**Last updated:**

15/04/2013

[View](/de/documents/overview/trajenta-epar-summary-public_de.pdf)

eesti keel (ET) (73.86 KB - PDF)

**First published:**

06/10/2011

**Last updated:**

15/04/2013

[View](/et/documents/overview/trajenta-epar-summary-public_et.pdf)

ελληνικά (EL) (103.19 KB - PDF)

**First published:**

06/10/2011

**Last updated:**

15/04/2013

[View](/el/documents/overview/trajenta-epar-summary-public_el.pdf)

français (FR) (75.69 KB - PDF)

**First published:**

06/10/2011

**Last updated:**

15/04/2013

[View](/fr/documents/overview/trajenta-epar-summary-public_fr.pdf)

italiano (IT) (74.31 KB - PDF)

**First published:**

06/10/2011

**Last updated:**

15/04/2013

[View](/it/documents/overview/trajenta-epar-summary-public_it.pdf)

latviešu valoda (LV) (98.04 KB - PDF)

**First published:**

06/10/2011

**Last updated:**

15/04/2013

[View](/lv/documents/overview/trajenta-epar-summary-public_lv.pdf)

lietuvių kalba (LT) (96.95 KB - PDF)

**First published:**

06/10/2011

**Last updated:**

15/04/2013

[View](/lt/documents/overview/trajenta-epar-summary-public_lt.pdf)

magyar (HU) (94.28 KB - PDF)

**First published:**

06/10/2011

**Last updated:**

15/04/2013

[View](/hu/documents/overview/trajenta-epar-summary-public_hu.pdf)

Malti (MT) (101.56 KB - PDF)

**First published:**

06/10/2011

**Last updated:**

15/04/2013

[View](/mt/documents/overview/trajenta-epar-summary-public_mt.pdf)

Nederlands (NL) (74.77 KB - PDF)

**First published:**

06/10/2011

**Last updated:**

15/04/2013

[View](/nl/documents/overview/trajenta-epar-summary-public_nl.pdf)

polski (PL) (100.03 KB - PDF)

**First published:**

06/10/2011

**Last updated:**

15/04/2013

[View](/pl/documents/overview/trajenta-epar-summary-public_pl.pdf)

português (PT) (96.87 KB - PDF)

**First published:**

06/10/2011

**Last updated:**

15/04/2013

[View](/pt/documents/overview/trajenta-epar-summary-public_pt.pdf)

română (RO) (96.59 KB - PDF)

**First published:**

06/10/2011

**Last updated:**

15/04/2013

[View](/ro/documents/overview/trajenta-epar-summary-public_ro.pdf)

slovenčina (SK) (100.08 KB - PDF)

**First published:**

06/10/2011

**Last updated:**

15/04/2013

[View](/sk/documents/overview/trajenta-epar-summary-public_sk.pdf)

slovenščina (SL) (90.89 KB - PDF)

**First published:**

06/10/2011

**Last updated:**

15/04/2013

[View](/sl/documents/overview/trajenta-epar-summary-public_sl.pdf)

Suomi (FI) (73.86 KB - PDF)

**First published:**

06/10/2011

**Last updated:**

15/04/2013

[View](/fi/documents/overview/trajenta-epar-summary-public_fi.pdf)

svenska (SV) (74.36 KB - PDF)

**First published:**

06/10/2011

**Last updated:**

15/04/2013

[View](/sv/documents/overview/trajenta-epar-summary-public_sv.pdf)

Trajenta : EPAR - Risk Management Plan

English (EN) (1.87 MB - PDF)

**First published:** 10/12/2019

**Last updated:** 17/05/2023

[View](/en/documents/rmp/trajenta-epar-risk-management-plan_en.pdf)

## Product information

Trajenta : EPAR - Product Information

English (EN) (221.37 KB - PDF)

**First published:** 06/10/2011

**Last updated:** 28/01/2025

[View](/en/documents/product-information/trajenta-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-471)

български (BG) (380.75 KB - PDF)

**First published:**

06/10/2011

**Last updated:**

28/01/2025

[View](/bg/documents/product-information/trajenta-epar-product-information_bg.pdf)

español (ES) (356.49 KB - PDF)

**First published:**

06/10/2011

**Last updated:**

28/01/2025

[View](/es/documents/product-information/trajenta-epar-product-information_es.pdf)

čeština (CS) (378.55 KB - PDF)

**First published:**

06/10/2011

**Last updated:**

28/01/2025

[View](/cs/documents/product-information/trajenta-epar-product-information_cs.pdf)

dansk (DA) (385.04 KB - PDF)

**First published:**

06/10/2011

**Last updated:**

28/01/2025

[View](/da/documents/product-information/trajenta-epar-product-information_da.pdf)

Deutsch (DE) (360.06 KB - PDF)

**First published:**

06/10/2011

**Last updated:**

28/01/2025

[View](/de/documents/product-information/trajenta-epar-product-information_de.pdf)

eesti keel (ET) (350.22 KB - PDF)

**First published:**

06/10/2011

**Last updated:**

28/01/2025

[View](/et/documents/product-information/trajenta-epar-product-information_et.pdf)

ελληνικά (EL) (378.43 KB - PDF)

**First published:**

06/10/2011

**Last updated:**

28/01/2025

[View](/el/documents/product-information/trajenta-epar-product-information_el.pdf)

français (FR) (378.81 KB - PDF)

**First published:**

06/10/2011

**Last updated:**

28/01/2025

[View](/fr/documents/product-information/trajenta-epar-product-information_fr.pdf)

hrvatski (HR) (361.09 KB - PDF)

**First published:**

06/10/2011

**Last updated:**

28/01/2025

[View](/hr/documents/product-information/trajenta-epar-product-information_hr.pdf)

íslenska (IS) (301.83 KB - PDF)

**First published:**

06/10/2011

**Last updated:**

28/01/2025

[View](/is/documents/product-information/trajenta-epar-product-information_is.pdf)

italiano (IT) (343.61 KB - PDF)

**First published:**

06/10/2011

**Last updated:**

28/01/2025

[View](/it/documents/product-information/trajenta-epar-product-information_it.pdf)

latviešu valoda (LV) (363.29 KB - PDF)

**First published:**

06/10/2011

**Last updated:**

28/01/2025

[View](/lv/documents/product-information/trajenta-epar-product-information_lv.pdf)

lietuvių kalba (LT) (378.83 KB - PDF)

**First published:**

06/10/2011

**Last updated:**

28/01/2025

[View](/lt/documents/product-information/trajenta-epar-product-information_lt.pdf)

magyar (HU) (413.2 KB - PDF)

**First published:**

06/10/2011

**Last updated:**

28/01/2025

[View](/hu/documents/product-information/trajenta-epar-product-information_hu.pdf)

Malti (MT) (400.32 KB - PDF)

**First published:**

06/10/2011

**Last updated:**

28/01/2025

[View](/mt/documents/product-information/trajenta-epar-product-information_mt.pdf)

Nederlands (NL) (353.12 KB - PDF)

**First published:**

06/10/2011

**Last updated:**

28/01/2025

[View](/nl/documents/product-information/trajenta-epar-product-information_nl.pdf)

norsk (NO) (303.65 KB - PDF)

**First published:**

06/10/2011

**Last updated:**

28/01/2025

[View](/no/documents/product-information/trajenta-epar-product-information_no.pdf)

polski (PL) (385.42 KB - PDF)

**First published:**

06/10/2011

**Last updated:**

28/01/2025

[View](/pl/documents/product-information/trajenta-epar-product-information_pl.pdf)

português (PT) (362.04 KB - PDF)

**First published:**

06/10/2011

**Last updated:**

28/01/2025

[View](/pt/documents/product-information/trajenta-epar-product-information_pt.pdf)

română (RO) (383.81 KB - PDF)

**First published:**

06/10/2011

**Last updated:**

28/01/2025

[View](/ro/documents/product-information/trajenta-epar-product-information_ro.pdf)

slovenčina (SK) (375.58 KB - PDF)

**First published:**

06/10/2011

**Last updated:**

28/01/2025

[View](/sk/documents/product-information/trajenta-epar-product-information_sk.pdf)

slovenščina (SL) (335.96 KB - PDF)

**First published:**

06/10/2011

**Last updated:**

28/01/2025

[View](/sl/documents/product-information/trajenta-epar-product-information_sl.pdf)

Suomi (FI) (352.93 KB - PDF)

**First published:**

06/10/2011

**Last updated:**

28/01/2025

[View](/fi/documents/product-information/trajenta-epar-product-information_fi.pdf)

svenska (SV) (362.47 KB - PDF)

**First published:**

06/10/2011

**Last updated:**

28/01/2025

[View](/sv/documents/product-information/trajenta-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** N/0058 24/01/2025

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Trajenta : EPAR - All Authorised presentations

English (EN) (64.96 KB - PDF)

**First published:** 06/10/2011

**Last updated:** 06/10/2011

[View](/en/documents/all-authorised-presentations/trajenta-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-916)

български (BG) (54.68 KB - PDF)

**First published:**

06/10/2011

**Last updated:**

06/10/2011

[View](/bg/documents/all-authorised-presentations/trajenta-epar-all-authorised-presentations_bg.pdf)

español (ES) (50.13 KB - PDF)

**First published:**

06/10/2011

**Last updated:**

06/10/2011

[View](/es/documents/all-authorised-presentations/trajenta-epar-all-authorised-presentations_es.pdf)

čeština (CS) (70.56 KB - PDF)

**First published:**

06/10/2011

**Last updated:**

06/10/2011

[View](/cs/documents/all-authorised-presentations/trajenta-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (50.26 KB - PDF)

**First published:**

06/10/2011

**Last updated:**

06/10/2011

[View](/da/documents/all-authorised-presentations/trajenta-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (91.31 KB - PDF)

**First published:**

06/10/2011

**Last updated:**

06/10/2011

[View](/de/documents/all-authorised-presentations/trajenta-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (48.01 KB - PDF)

**First published:**

06/10/2011

**Last updated:**

06/10/2011

[View](/et/documents/all-authorised-presentations/trajenta-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (63.2 KB - PDF)

**First published:**

06/10/2011

**Last updated:**

06/10/2011

[View](/el/documents/all-authorised-presentations/trajenta-epar-all-authorised-presentations_el.pdf)

français (FR) (51.27 KB - PDF)

**First published:**

06/10/2011

**Last updated:**

06/10/2011

[View](/fr/documents/all-authorised-presentations/trajenta-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (57.05 KB - PDF)

**First published:**

06/10/2011

**Last updated:**

06/10/2011

[View](/hr/documents/all-authorised-presentations/trajenta-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (49.47 KB - PDF)

**First published:**

06/10/2011

**Last updated:**

06/10/2011

[View](/is/documents/all-authorised-presentations/trajenta-epar-all-authorised-presentations_is.pdf)

italiano (IT) (49.51 KB - PDF)

**First published:**

06/10/2011

**Last updated:**

06/10/2011

[View](/it/documents/all-authorised-presentations/trajenta-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (81.19 KB - PDF)

**First published:**

06/10/2011

**Last updated:**

06/10/2011

[View](/lv/documents/all-authorised-presentations/trajenta-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (82.4 KB - PDF)

**First published:**

06/10/2011

**Last updated:**

06/10/2011

[View](/lt/documents/all-authorised-presentations/trajenta-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (79.92 KB - PDF)

**First published:**

06/10/2011

**Last updated:**

06/10/2011

[View](/hu/documents/all-authorised-presentations/trajenta-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (79.49 KB - PDF)

**First published:**

06/10/2011

**Last updated:**

06/10/2011

[View](/mt/documents/all-authorised-presentations/trajenta-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (63.34 KB - PDF)

**First published:**

06/10/2011

**Last updated:**

06/10/2011

[View](/nl/documents/all-authorised-presentations/trajenta-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (49.32 KB - PDF)

**First published:**

06/10/2011

**Last updated:**

06/10/2011

[View](/no/documents/all-authorised-presentations/trajenta-epar-all-authorised-presentations_no.pdf)

polski (PL) (72.56 KB - PDF)

**First published:**

06/10/2011

**Last updated:**

06/10/2011

[View](/pl/documents/all-authorised-presentations/trajenta-epar-all-authorised-presentations_pl.pdf)

português (PT) (50.42 KB - PDF)

**First published:**

06/10/2011

**Last updated:**

06/10/2011

[View](/pt/documents/all-authorised-presentations/trajenta-epar-all-authorised-presentations_pt.pdf)

română (RO) (54.08 KB - PDF)

**First published:**

06/10/2011

**Last updated:**

06/10/2011

[View](/ro/documents/all-authorised-presentations/trajenta-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (77.44 KB - PDF)

**First published:**

06/10/2011

**Last updated:**

06/10/2011

[View](/sk/documents/all-authorised-presentations/trajenta-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (26.78 KB - PDF)

**First published:**

06/10/2011

**Last updated:**

06/10/2011

[View](/sl/documents/all-authorised-presentations/trajenta-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (64.64 KB - PDF)

**First published:**

06/10/2011

**Last updated:**

06/10/2011

[View](/fi/documents/all-authorised-presentations/trajenta-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (50.36 KB - PDF)

**First published:**

06/10/2011

**Last updated:**

06/10/2011

[View](/sv/documents/all-authorised-presentations/trajenta-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Trajenta Active substance linagliptin International non-proprietary name (INN) or common name linagliptin Therapeutic area (MeSH) Diabetes Mellitus, Type 2 Anatomical therapeutic chemical (ATC) code A10BH05

### Pharmacotherapeutic group

Drugs used in diabetes

### Therapeutic indication

Trajenta is indicated in the treatment of type 2 diabetes mellitus to improve glycaemic control in adults:

as **monotherapy**

- in patients inadequately controlled by diet and exercise alone and for whom metformin is inappropriate due to intolerance, or contraindicated due to renal impairment.

as **combination therapy**

- in combination with metformin when diet and exercise plus metformin alone do not provide adequate glycaemic control.
- in combination with a sulphonylurea and metformin when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control.
- in combination with insulin with or without metformin, when this regimen alone, with diet and exercise, does not provide adequate glycaemic control.

## Authorisation details

EMA product number EMEA/H/C/002110 Marketing authorisation holder

Boehringer Ingelheim International GmbH

Binger Strasse 173

Marketing authorisation issued 23/08/2011 Revision 22

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Trajenta : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (197.6 KB - PDF)

**First published:** 03/05/2012

**Last updated:** 28/01/2025

[View](/en/documents/procedural-steps-after/trajenta-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

Trajenta - EPAR - Paediatric investigation plan compliance statement

Reference Number: EMA/CHMP/141255/2023

English (EN) (110.63 KB - PDF)

**First published:** 10/05/2023

[View](/en/documents/pip-compliance/trajenta-epar-paediatric-investigation-plan-compliance-statement_en.pdf)

Trajenta-H-C-002110-II-0049 : EPAR - Assessment Report - Variation

Adopted

Reference Number: EMA/212741/2023

English (EN) (1.62 MB - PDF)

**First published:** 10/05/2023

[View](/en/documents/variation-report/trajenta-h-c-002110-ii-0049-epar-assessment-report-variation_en.pdf)

Trajenta-H-C-2110-WS0915 : EPAR - Assessment Report - Variation

Adopted

Reference Number: EMA/ /215439/2017

English (EN) (1.5 MB - PDF)

**First published:** 12/07/2018

**Last updated:** 12/07/2018

[View](/en/documents/variation-report/trajenta-h-c-2110-ws0915-epar-assessment-report-variation_en.pdf)

CHMP Post-authorisation summary of positive opinion for Trajenta (CHMP)

English (EN) (71.47 KB - PDF)

**First published:** 16/12/2016

**Last updated:** 16/12/2016

[View](/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-trajenta-chmp_en.pdf)

Trajenta : EPAR - Scientific conclusions and grounds recommending the variation to the terms of the marketing authorisation

Reference Number: EMA/83549/2016

English (EN) (68.33 KB - PDF)

**First published:** 14/03/2016

**Last updated:** 14/03/2016

[View](/en/documents/scientific-conclusion/trajenta-epar-scientific-conclusions-and-grounds-recommending-variation-terms-marketing-authorisation_en.pdf)

Trajenta-H-C-2110-II-0004-G : EPAR - Assessment Report - Variation

Adopted

Reference Number: EMA/CHMP/508574/2012

English (EN) (1.35 MB - PDF)

**First published:** 05/12/2012

**Last updated:** 05/12/2012

[View](/en/documents/variation-report/trajenta-h-c-2110-ii-0004-g-epar-assessment-report-variation_en.pdf)

CHMP post-authorisation summary of positive opinion for Trajenta

Adopted

Reference Number: EMA/591330/2012

English (EN) (58.85 KB - PDF)

**First published:** 21/09/2012

**Last updated:** 21/09/2012

[View](/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-trajenta_en.pdf)

## Initial marketing authorisation documents

Trajenta : EPAR - Public assessment report

Adopted

Reference Number: EMA/604444/2011

English (EN) (1.23 MB - PDF)

**First published:** 06/10/2011

**Last updated:** 06/10/2011

[View](/en/documents/assessment-report/trajenta-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for Trajenta

Adopted

Reference Number: EMA/CHMP/450821/2011

English (EN) (53.4 KB - PDF)

**First published:** 24/06/2011

**Last updated:** 24/06/2011

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-trajenta_en.pdf)

#### News on Trajenta

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2013](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2013) 26/07/2013

[Investigation into GLP-1-based diabetes therapies concluded](/en/news/investigation-glp-1-based-diabetes-therapies-concluded) 26/07/2013

[European Medicines Agency investigates findings on pancreatic risks with GLP-1-based therapies for type-2 diabetes](/en/news/european-medicines-agency-investigates-findings-pancreatic-risks-glp-1-based-therapies-type-2-diabetes) 26/03/2013

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 17-20 September 2012](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-17-20-september-2012) 21/09/2012

- [Clinical data](https://clinicaldata.ema.europa.eu/web/cdp/home?p_p_id=cdpdossierviewportlet_WAR_cdpdossierviewportlet=0=maximized=view=column-3=2=EMEAHC002110WS0915) (variation WS0915)

#### More information on Trajenta

- [EMEA-000498-PIP01-08-M10 - paediatric investigation plan](/en/medicines/human/paediatric-investigation-plans/emea-000498-pip01-08-m10)

#### Topics

- [Medicines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A61)

**This page was last updated on** 28/01/2025

## Share this page

[Back to top](#main-content)